With interest in testing remdesivir against Covid-19 ramping up, Gilead has moved to increase the chances that its two studies will yield something positive.
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
Cellex wins the race to get the FDA’s buy-in for a blood test to pinpoint immunity.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
In the past week the US FDA has granted emergency use authorisation for a further seven in vitro diagnostics for Covid-19 infection, bringing the total to 16.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Statements this week from Public Health England that the UK would soon start mass testing to identify people who have had a Covid-19 infection and recovered, and are therefore immune, have thrown the spotlight on developers of these antibody-based blood tests.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s a lot.
Last week Vantage highlighted 315 pivotal trials that are approaching readout and that could face delays caused by the new coronavirus pandemic. A further analysis seeks to put a figure on exactly how much cash is being put to work here: $20bn is the figure that EvaluatePharma Vision* estimates it will cost to run these 315 studies.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
A Vantage analysis identifies 315 pivotal trials that risk, like Lexicon’s Scored and Soloist studies, never being completed.
The fates of companies that have obtained FDA emergency use authorisation for their sequencing-based tests for the novel coronavirus have diverged wildly, judging by their share price performance in the trading period after the EUA was granted.
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
One thing is certain from the ongoing Covid-19 pandemic: hospitals and healthcare systems need more respirators.
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
Thanks to the FDA, Hologic and Labcorp have managed to arrest the damage they sustained during yesterday’s bloodbath on the exchanges: their shares are up very slightly after the agency granted emergency use authorisation to their Covid-19 diagnostics.
As Cepi asks for $2bn to fund development of a vaccine against coronavirus and Moderna moves into the clinic, Vantage takes a look at previous pandemic development costs.
The race between diagnostics companies to be the first to get the FDA’s authorisation for a Covid-19 assay was declared a draw on Friday, with both Roche and Thermo Fisher gaining emergency use authorisation for their respective tests.
Money will of course be no object when it comes to funding development of treatments for Covid-19, but how much exactly are we talking?
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
Much of the world’s vaccine manufacturing capacity lies with a fairly small number of companies – in the west, at least – and it is to these groups that the World Health Organization would likely turn should a preventative treatment for Covid-19 be found.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
Vaccine makers managed to respond pretty quickly to previous viral outbreaks – swine flu and avian flu specifically – and certain companies are still booking sales of these preventative shots, EvaluatePharma data show.
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
The Covid-19 outbreak has highlighted the need for effective broad-spectrum antivirals that can be stockpiled for times of need; a look at historic sales of existing agents shows how use spiked during previous outbreaks.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.